4//SEC Filing
FREEMAN SCOTT M 4
Accession 0001209191-04-020183
CIK 0001012140other
Filed
Apr 8, 8:00 PM ET
Accepted
Apr 9, 4:58 PM ET
Size
15.2 KB
Accession
0001209191-04-020183
Insider Transaction Report
Form 4
FREEMAN SCOTT M
VP, Clinical Research
Transactions
- Sale
Common Stock
2004-04-08$43.57/sh−3,243$141,298→ 4,346 total - Exercise/Conversion
Stock Option (Right to Buy)
2004-04-08−5,000→ 10,000 totalExercise: $4.00From: 2003-01-22Exp: 2012-07-21→ Common Stock (5,000 underlying) - Sale
Common Stock
2004-04-08$43.63/sh−300$13,089→ 8,814 total - Sale
Common Stock
2004-04-08$43.58/sh−232$10,111→ 4,114 total - Exercise/Conversion
Common Stock
2004-04-08$4.00/sh+5,000$20,000→ 9,114 total - Sale
Common Stock
2004-04-08$43.60/sh−1,125$49,050→ 7,689 total - Sale
Common Stock
2004-04-08$43.61/sh−100$4,361→ 7,589 total
Footnotes (1)
- [F1]The shares subject to the option become exercisable at a rate of 12.5% on the date 6 months after the date of grant and in equal monthly installments thereafter for 42 months.
Documents
Issuer
ONYX PHARMACEUTICALS INC
CIK 0001012140
Entity typeother
Related Parties
1- filerCIK 0001282731
Filing Metadata
- Form type
- 4
- Filed
- Apr 8, 8:00 PM ET
- Accepted
- Apr 9, 4:58 PM ET
- Size
- 15.2 KB